Merck (MRK) Other Accumulated Expenses (2009 - 2026)

Merck (MRK) has reported Other Accumulated Expenses for 18 consecutive years, with $14.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 13.91% year-over-year to $14.5 billion; the TTM figure through Mar 2026 stood at $14.5 billion (up 13.91% YoY), while the FY2025 annual figure was $14.5 billion, down 7.81% from the prior year.
• Other Accumulated Expenses rose to $14.5 billion in Q1 2026 per MRK's latest filing, from $14.5 billion in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $16.5 billion in Q3 2024 and bottomed at $12.8 billion in Q1 2025.
• Historically, Other Accumulated Expenses has averaged $14.5 billion across 5 years, with a median of $14.5 billion in 2025.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses grew 17.97% — and 2025, when it fell 9.43%.
• Merck's Other Accumulated Expenses stood at $14.2 billion in 2022, then grew by 11.35% to $15.8 billion in 2023, then decreased by 0.46% to $15.7 billion in 2024, then fell by 7.81% to $14.5 billion in 2025, then advanced by 0.56% to $14.5 billion in 2026.
• Business Quant data shows MRK's Other Accumulated Expenses at $14.5 billion in Q1 2026, $14.5 billion in Q4 2025, and $16.2 billion in Q3 2025.